Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6665065 | 0.84 | LOXL2 (0.41) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL28605200 | 0.80 | HRH1 (0.42) | KDM4EGPR3EGFRCYP1A2MAPT | |
| SCHEMBL874900 | 0.79 | KMT2A (0.44) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL6597830 | 0.79 | SORD (0.47) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL290894 | 0.79 | KDM4E (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL1514912 | 0.79 | CYP1A2 (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL9971234 | 0.79 | KDM4E (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL9934866 | 0.79 | KDM4E (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL29756554 | 0.79 | KMT2A (0.44) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL30838793 | 0.79 | CYP1A2 (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891363-B1 | Multi-target drug candidates for the treatment of triple-negative breast cancer | King Faisal University (SA) | 2024-02-06 | — | — | US | claimed |
| EP-3510404-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | claimed |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | claimed |
| WO-2018048928-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | claimed |
| US-11970464-B1 | Multi-target drug candidates for the treatment of triple-negative breast cancer | King Faisal University (SA) | 2024-04-30 | — | — | US | disclosed |
| US-11964947-B1 | Multi-target drug candidates for the treatment of triple-negative breast cancer | King Faisal University (SA) | 2024-04-23 | — | — | US | disclosed |
| US-11891363-B1 | Multi-target drug candidates for the treatment of triple-negative breast cancer | King Faisal University (SA) | 2024-02-06 | — | — | US | disclosed |
| EP-3510404-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2018048928-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-8440674-B2 | Substituted pyrimidine compounds as RAF inhibitors and methods of use | AMGEN INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-1976836-B9 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2013-02-06 | — | — | EP | disclosed |
| CN-1701076-A | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans | WYETH CORP (US) | 2005-11-23 | — | — | CN | disclosed |
| CN-1701075-A | Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines | WYETH CORP (US) | 2005-11-23 | — | — | CN | disclosed |
| CN-1681820-A | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans | WYETH CORP (US) | 2005-10-12 | — | — | CN | disclosed |
| CN-1681821-A | Antidepressivt virkende cykloalkylaminderivater AV heterocykle-kondenserte benzodioksaner | WYETH CORP (US) | 2005-10-12 | — | — | CN | disclosed |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2004-05-27 | — | — | US | disclosed |
| CN-1420882-A | Substd. oxoazaheterocyclyl compounds | AVENTIS PHARM PROD INC (US) | 2003-05-28 | — | — | CN | disclosed |
| EP-1208097-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | Aventis Pharmaceuticals Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001007436-A2 | SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS | AVENTIS PHARMACEUTICALS INC. (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964947-B1 | Multi-target drug candidates for the treatment of triple-negative breast cancer | BRCA1, HSP90AB1, HSF1 | KDM4E 2904/4885GPR3 3696/4885EGFR 488/4885 |
| US-20040102450-A1 | Substituted oxoazaheterocyclyl compounds | F13B, F9, F11 | KDM4E 2943/4885GPR3 4428/4885EGFR 2327/4885 |
| US-11970464-B1 | Multi-target drug candidates for the treatment of triple-negative breast cancer | BRCA1, HSP90AB1, HSF1 | KDM4E 2904/4885GPR3 3696/4885EGFR 488/4885 |
| US-11891363-B1 | Multi-target drug candidates for the treatment of triple-negative breast cancer | BRCA1, HSP90AB1, HSF1 | KDM4E 2904/4885GPR3 3696/4885EGFR 488/4885 |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | LOXL2, LOXL1, LOXL3 | KDM4E 3469/4885GPR3 516/4885EGFR 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.